Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) hit a new 52-week low during trading on Wednesday . The stock traded as low as $18.75 and last traded at $19.09, with a volume of 154,690 shares trading hands. The stock had previously closed at $19.86.

NTLA has been the subject of several research reports. Credit Suisse Group AG initiated coverage on Intellia Therapeutics in a research note on Tuesday, May 31st. They issued an “outperform” rating and a $39.00 target price for the company. Jefferies Group began coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They issued a “hold” rating and a $33.00 price target on the stock. Wedbush began coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They issued an “outperform” rating and a $38.00 price target on the stock. Finally, Leerink Swann began coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They issued a “market perform” rating and a $32.00 price target on the stock.

The firm’s market cap is $684.28 million. The firm’s 50-day moving average is $26.29 and its 200 day moving average is $25.97.

In other Intellia Therapeutics news, Director Carl L. Gordon acquired 250,000 shares of the business’s stock in a transaction on Wednesday, May 11th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $4,500,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Bros. Advisors Lp Baker acquired 200,000 shares of the business’s stock in a transaction on Wednesday, May 11th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $3,600,000.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.